Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the emerging role of PARP inhibitors in prostate cancer. A lack of known prognostic biomarkers presents a challenge in prostate cancer treatment. However, mutations in genes from the HRR pathway, including BRCA1, BRCA2 and ATM mutations, have recently been reported in 20-25% of patients with prostate cancer. Patients with prostate cancer who have these mutations may be suitable to receive PARP inhibitor therapy. The clinical efficacy of olaparib in patients with metastatic castration-resistant prostate cancer has been validated in the Phase III PROfound trial (NCT02987543). Phase II trials investigating rucaparib and niraparib have also shown promising early results. This interview took place during the 2021 Genitourinary Cancers Symposium.
Dr Giuseppe Procopio, MD, has participated in an advisory role for AstraZeneca, Bayer, Ipsen, Janssen, Merckx, MSD Pharmaceuticals, Novartis, Pfizer and BMS.